Abstract:Objective To study the relationship of plasma homocysteine (Hcy), bone turnover biomarkers (BTB), and bone mineral density (BMD) with osteoporotic fracture (OPF) in elderly people. Methods Eighty-two patients (aged 65 years or older) admitted to our orthopedics department between October 2014 and May 2015 were randomly divided into three groups: 1) OPF group: 39 cases with the mean age 81.82±5.49 years, which included 24 females and 15 males; 2) high-energy fracture (HEF) group: 22 cases with the mean age 78.88±5.75 years, which included 16 females and six males; 3) non-bone-fracture group: 21 cases with mean age 79.75±5.47 years without bone fracture, which included 14 females and seven males. Plasma Hcy, BTB, and BMD were measured. Analysis of variance and multiple regression analysis were used in the statistical analysis. Results There was no significant difference in either age or sex among the three groups. There were significant differences in plasma Hcy and hip BMD between the OPF and HEF groups; there was also significant difference in plasma Hcy, 25-(OH) Vit D, and hip BMD between the OPF and non-fracture groups. There was no difference in lumbar spine BMD between the OPF group and the other two groups. There was no significant difference in plasma Hcy, 25-(OH) Vit D, hip or lumbar spine BMD between the HEF and non-fracture group. There was no significant difference in procollagen type I N-propeptide of type I collagen, serum C-terminal cross-linking telopeptide of type I collagen, and parathyroid hormone among the three groups. Plasma Hcy was linearly correlated with age and serum C-terminal cross-linking telopeptide of type I collagen, but not correlated with either hip or lumbar spine BMD or any other BTBs. Conclusion In this study, we found that the plasma Hcy level in elderly patients with OPF is higher than that of nonosteoporotic patients. It is not correlated with BMD, but positively correlated with bone resorption markers. An increased Hcy level appears to be a risk factor for OPFs in elderly people.

Homocysteine as a Pathological Biomarker for Bone Disease

Homocysteine induces oxidative stress and ferroptosis of nucleus pulposus via enhancing methylation of GPX4.

Homocysteine mediated decrease in bone blood flow and remodeling: Role of folic acid

Clinical Significance of Plasma Homocysteine in the Coronary Atherosclerosis Patients

Association Between Plasma Total Homocysteine Level Within Normal Range and Bone Mineral Density in Adults

Homocysteine and Hyperhomocysteinaemia

Hydrogen sulfide attenuates homocysteine‐induced osteoblast dysfunction by inhibiting mitochondrial toxicity

The metabolism and significance of homocysteine in nutrition and health

Hydrogen Sulfide Promotes Bone Homeostasis by Balancing Inflammatory Cytokine Signaling in CBS-Deficient Mice through an Epigenetic Mechanism

Disturbed homocysteine metabolism is associated with cancer

Moderate Elevation of Homocysteine Induces Endothelial Dysfunction through Adaptive UPR Activation and Metabolic Rewiring

Impact of homocysteine on vasculogenic factors and bone formation in chicken embryos

Arrhythmia and neuronal/endothelial myocyte uncoupling in hyperhomocysteinemia

Impact of Hyperhomocysteinemia on Cytokine and Matrix Metalloproteinases Contents in Rat Skeletal Muscle

Mitochondrial mechanism of oxidative stress and systemic hypertension in hyperhomocysteinemia

Cardiovascular pathogenesis in hyperhomocysteinemia

Cardiac Dys-Synchronization and Arrhythmia in Hyperhomocysteinemia

The Contribution of Homocysteine Metabolism Disruption to Endothelial Dysfunction: State-of-the-Art

Cysteine and homocysteine as biomarker of various diseases

Folate ameliorates homocysteine-induced osteoblast dysfunction by reducing endoplasmic reticulum stress-activated PERK/ATF-4/CHOP pathway in MC3T3-E1 cells

Plasma Homocysteine Level is a Risk Factor for Osteoporotic Fractures in Elderly Patients